Seagen Inc.

09/26/2022 | Press release | Distributed by Public on 09/26/2022 06:10

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid[...]